BioCryst Pharma (BCRX) Appoints Helen Thackray, M.D., as Chief Research and Development Officer

Go back to BioCryst Pharma (BCRX) Appoints Helen Thackray, M.D., as Chief Research and Development Officer

BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer

March 19, 2021 7:00 AM EDT

RESEARCH TRIANGLE PARK, N.C., March 19, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly created position of chief research and development officer.

In this role, Dr. Thackray will be responsible for continuing to build the companys portfolio of rare disease... More